FibroGen

FibroGen shares take a beating as CEO reveals safety data manipulation for its blockbuster contender roxadustat
FibroGen shares take a beating as CEO reveals safety data manipulation for its blockbuster contender roxadustat
Endpoints
FibroGen
anemia
roxadustat
Flag link:
FibroGen shares skid lower as a surprise adcomm raises risks on roxa OK
FibroGen shares skid lower as a surprise adcomm raises risks on roxa OK
Endpoints
FibroGen
roxadustat
FDA
advisory panel
Flag link:
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:
AstraZeneca, FibroGen's roxadustat hits snag at FDA, but analysts figure an approval's still on its way
AstraZeneca, FibroGen's roxadustat hits snag at FDA, but analysts figure an approval's still on its way
Fierce Pharma
AstraZeneca
FibroGen
roxadustat
FDA
anemia
Flag link:
Astellas, FibroGen get approval in Japan for Evrenzo to treat anaemia of CKD in adult patients not on dialysis
Astellas, FibroGen get approval in Japan for Evrenzo to treat anaemia of CKD in adult patients not on dialysis
Pharmaceutical Business Review
Astellas
FibroGen
Japan
Evrenzo
chronic kidney disease
Flag link:
FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease
FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease
BioSpace
FibroGen
roxadustat
ASN
chronic kidney disease
Flag link:
5 FDA approval decisions to watch in the 4th quarter
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
FDA
drug approvals
vaccines
Pfizer
Moderna Therapeutics
COVID-19
Regeneron
EB3
ebola virus
Alkermes
ALKS-3831
schizophrenia
bipolar disorder
Bristol-Myers Squibb
liso-cel
non-Hodgkin lymphoma
roxadustat
FibroGen
chronic kidney disease
Flag link:
Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug in broad chronic kidney disease population
Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug in broad chronic kidney disease population
Endpoints
FibroGen
AstraZeneca
FDA
anemia
chronic kidney disease
roxadustat
Flag link:
Data From 3 Roxadustat Trials Lead Off Kidney Week Sessions Ahead of Efficacy, Safety News
Data From 3 Roxadustat Trials Lead Off Kidney Week Sessions Ahead of Efficacy, Safety News
Managed Markets Network
nephrology
roxadustat
AstraZeneca
FibroGen
kidney disease
Flag link:
FibroGen founder Thomas Neff dies suddenly as drug he championed racks up milestones
FibroGen founder Thomas Neff dies suddenly as drug he championed racks up milestones
Fierce Pharma
FibroGen
Thomas Neff
Pharma CEOs
roxadustat
Flag link:
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
Yahoo/Zacks.com
AstraZeneca
FibroGen
China
roxadustat
chronic kidney disease
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
Yahoo/Benzinga
Retrophin
Karyopharm
Celyad
uniQure
Sangamo Therapeutics
Catalyst Biosciences
Novo Nordisk
Reata Pharmaceuticals
Vertex Pharmaceuticals
Bellicum
Gilead Sciences
Jaguar Health
TRACON Pharmaceuticals
FibroGen
Aslan Pharma
ObsEva
Sorrento Therapeutics
Flag link:
Roxadustat safety analysis provokes more questions than answers
Roxadustat safety analysis provokes more questions than answers
EP Vantage
FibroGen
roxadustar
anemia
AstraZeneca
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Yahoo/Benzinga
FDA
Novartis
Ascendis
Eiger BioPharmaceuticals
Proteostasis Therapeutics
Fibrocell Science
Supernus Pharmaceuticals
FibroGen
INSYS Therapeutics
Flag link:
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
EP Vantage
FibroGen
roxadustat
pamrevlumab
Duchenne Muscular Dystrophy
givosiran
Alnylam
Flag link:
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
CP Wire
FibroGen
pamrevlumab
IPF
idiopathic pulmonary fibrosis
Flag link:
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
FibroGen
pamrevlumab
idiopathic pulmonary fibrosis
Flag link:
Galapagos spotlights an ‘exciting’ round of PoC data for IPF drug, shares surge
Galapagos spotlights an ‘exciting’ round of PoC data for IPF drug, shares surge
Endpoints
Galapagos
IPF
GLPG1690
FibroGen
Flag link:
FibroGen Has The Look Of A Long-Term Biotech Winner
FibroGen Has The Look Of A Long-Term Biotech Winner
Seeking Alpha
FibroGen
roxadustat
kidney disease
Flag link:
9 Biotech Picks for 2016
9 Biotech Picks for 2016
Barron's
biotech
Adaptimmune
Dermira
FibroGen
Incyte
Intra-Cellular Therapies
Seres Therapeutics
Ophthotech
Neurocrine Biosciences
Paratek
Flag link:

Pages